News About SaNOtize Nasal Spray (Enovid)

Clinical Study Suggests SaNOtize Nitric Oxide Nasal Spray Is Effective at Preventing COVID-19 after High-Risk Exposure

On May 31, 2022 0 Comment

Published on May 11, 2022 on Businesswire.com. After confirmed exposure to COVID-19, infection rate in participants (n=625) who took NONS™ was 6.4% versus 25.6% in the control group (P<0.0001). The new data build upon previously reported Phase III trial results demonstrating that a rapid reduction of viral load prevents progression to infection after COVID-19 exposure. The new study, conducted at Srinakharinwirot University in Bangkok, Thailand, found participants who took NONS after COVID-19 exposure were 75% less likely to become infected when compared to the control group, yielding a statistically significant reduction in infection rate. The study was carried out during an...

Phase 3 Clinical Trial Confirms SaNOtize’s Treatment is 99% Effective Against COVID-19

On February 10, 2022 0 Comment

SaNOtize and Glenmark Pharmaceuticals Limited has announced on February 09, 2022: Phase 3 trial reached primary endpoint and demonstrated a reduction in SARS-CoV-2 log viral load in COVID-19 patients by more than 94% within 24 hours of treatment, and by more than 99% in 48 hours Treatment also demonstrated, in the high-risk group (n=218), a greater proportion of patients who achieved a combination of clinical and virological cure, based on the WHO Progression Scale Median time to virological cure was 4 days in the treatment group, 8 days in the placebo group (p < 0.05). A Phase 3 clinical trial was...

Outstanding Preliminary Results of A Clinical Trial Treating Moderate-To-Severe Covid-19 Patients, Conducted By Amorphical, An Israeli Biotechnology Company

On January 09, 2022 0 Comment

Amorphical, an Israeli biotech company developing Amorphous Calcium Carbonate (ACC) has announced results of a phase II clinical trial. Amorphical’s Novel COVID-19 Amorphous Calcium Carbonate (ACC) Treatment Significantly Reduces the Risk of ICU Admission and Mortality in Interim Analysis of a Phase II Study Involving Patients Hospitalized with Moderate-to-Severe COVID-19. (NIH Clinical Trial Registration No. NCT04900337) Published by Amorphical, Ness Ziyona, Israel | January 06, 2022 https://newsdirect.com/news/outstanding-preliminary-results-of-a-clinical-trial-treating-moderate-to-severe-covid-19-patients-conducted-by-amorphical-an-israeli-biotechnology-company-973592489 Read more on the Jerusalem Post (published December 22, 2021): https://www.jpost.com/health-and-wellness/coronavirus/article-689543

SaNOtize faces increased demand and is now seeking to raise funds to support production expansion

On November 13, 2021 0 Comment

SaNOtize reports that NONS sales in Q3 2021 were $5M and are projected to exceed $9M by the end of 2021. SaNOtize anticipates 2022 revenues will be $70-100M - the timing of approvals in various countries is a key driver of sales volume. With healthy contribution margins, the company believes it could be cash flow positive by the end of 2022. The company is now raising additional funds through OurCrowd platform; To read more about this investment opportunity, here is a link to SaNOtize's company page.

BNN Bloomberg: An Interview with Dr. Gilly Regev of SaNOtize

On November 13, 2021 0 Comment

U.K. clinical trials for Vancouver’s SaNOtize have confirmed that its nasal spray reduced SARS-CoV-2 log viral load by more than 95 per cent in infected participants within 24 hours of treatment, and by more than 99 per cent in 72 hours. While the product is set to sell over the counter in Israel and New Zealand pharmacies, Dr. Gilly Regev says Health Canada sees their product as a drug and not a medical device, hindering the ability for SaNOtize to be available to the Canadian market sooner rather than later.